Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Oct 3 - Oct 8
Phase III results for retatrutide are set to be released later in 2025 and in early 2026, but an earlier phase II trial recorded between a 7.2% and 17.5% reduction in body weight after 24 weeks, depending on the dose (7.2% on 1mg, 17.5% on 12mg), and up to a 24.2% reduction in body weight after 48 weeks for those on 12mg (-8.7% change for those on 1mg) 8
Ideal candidates include those with treatment-resistant depression, individuals needing quick relief from severe symptoms, or those looking for a non-oral, integrative mental health option
Fruits contain a wide range of vitamins and minerals that are essential for overall health
By 24 hours post-injection, greater than 95% of the previous dose has cleared from circulation, making daily administration feasible for sustained research protocols without reaching toxic plasma concentrations
US$ 29.38
US$ 28.85
US$ 22.63
US$ 23.94
